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doi:10.1Objective: Current American Heart Association/American College of Cardiology guidelines recommend antico-
agulation and antiplatelet therapy during the first 90 postoperative days; however, there is wide variability in the
administration of antithrombotic therapy after bioprosthetic aortic valve replacement. We sought to determine
whether early antithrombotic therapy was necessary in patients undergoing isolated bioprosthetic aortic valve im-
plantation and who were discharged in normal sinus rhythm.
Methods: From December 2001 to October 2008, 1131 patients underwent isolated bioprosthetic aortic valve
implantation at Brigham and Women’s Hospital. After exclusion of patients who underwent concomitant oper-
ations (n ¼ 138, 12%), patients who were anticoagulated preoperatively (n ¼ 4, 0.4%), and patients who expe-
rienced postoperative refractory atrial fibrillation requiring anticoagulation at discharge (n ¼ 128, 11%), our
study base consisted of 861 patients. Patients were followed for 90 days postoperatively for the occurrence of
thromboembolism, including stroke, transient ischemic attack, or peripheral thromboembolic events and bleeding
complications.
Results: Of the 861 patients included in this study, 133 (15%) were anticoagulated with warfarin sodium (ACþ)
postoperatively and 728 (85%) were not (AC). Patients who received postoperative anticoagulation were older;
had a higher incidence of hypertension, cerebrovascular accident, and pulmonary vascular disease; and were more
symptomatic at presentation. The 90-day risk of thromboembolism (cerebrovascular accident, transient ischemic
attack, or peripheral thromboembolism) after surgery was 5% (n ¼ 6) in those who were anticoagulated and 5%
(n¼ 39) in those who were not (P¼ .67). Independent predictors of thromboembolism were found to be increas-
ing age (odds ratio, 1.03; P ¼ .03), female gender (odds ratio, 2.23; P ¼ .005), short stature (odds ratio, 0.97;
P ¼ .002), smoking status (P ¼ .05), New York Heart Association III/IV (odds ratio 1.77, P ¼ .04), and
a 19-mm bioprosthetic aortic valve prosthesis (odds ratio, 2.22; P¼ .03). Evaluation of each predictor with post-
operative acetylsalicylic acidþand ACþinteraction terms revealed that female patients (odds ratio, 0.75; P ¼ .03
ACþ; odds ratio, 0.66; P ¼ .02 acetylsalicylic acidþ) and patients with a 19-mm bioprosthetic aortic valve (odds
ratio, 0.65; P¼ .02 ACþ; odds ratio, 0.36; P¼ .01 acetylsalicylic acidþ) had a reduction in the incidence of throm-
boembolism when administered acetylsalicylic acid or warfarin sodium. Patients who were in New York Heart
Association III/IV also had a reduction of thromboembolism when given vitamin K antagonist (odds ratio, 0.73;
P ¼ .04); a similar trend was observed in patients given acetylsalicylic acid (odds ratio, 0.34; P ¼ .06).
Conclusion: Early anticoagulation after isolated bioprosthetic aortic valve replacement in patients in normal si-
nus rhythm does not seem to reduce the risk of thromboembolism except in high-risk groups. Current recommen-
dations should be revisited, because the only patients whomay benefit from anticoagulation are female, those who
are highly symptomatic, and those with a small aortic prosthesis. (J Thorac Cardiovasc Surg 2010;139:1137-45)The use of a bioprosthetic aortic valve (BPAV) is associated
with both advantages and disadvantages when compared
with the alternative mechanical valve. The durability of
a BPAV is limited; however, most patients are protectede Division of Cardiac Surgery, Brigham andWomen’s Hospital, HarvardMed-
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The Journal of Thoracic and Carfrom the use of chronic anticoagulation, which may be
particularly beneficial to those at high risk of bleeding com-
plications (eg, elderly, fall risk). Although there is a general
consensus that long-term anticoagulation with BPAV is
unnecessary, there continues to be much debate regarding
the necessity of anticoagulation in the immediate postopera-
tive period. The most recent American Heart Association/
American College of Cardiology and European Society of
Cardiology recommendations include anticoagulation for
90 days postoperatively with a vitamin K antagonist
(VKA), such as warfarin sodium, and antiplatelet therapy
with acetylsalicylic acid (ASA).1-3 These recommendations
seem to based solely on a single institution study that dem-
onstrated a high incidence of thromboembolism (TE) in thediovascular Surgery c Volume 139, Number 5 1137
Abbreviations and Acronyms
ASA ¼ acetylsalicylic acid
BPAV ¼ bioprosthetic aortic valve
CVA ¼ cerebrovascular accident
NYHA ¼ New York Heart Association
PPM ¼ prosthesis–patient mismatch
TE ¼ thromboembolism
TIA ¼ transient ischemic attack
VKA ¼ vitamin K antagonist
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Dfirst 10 postoperative days in patients who were not antico-
agulated.4 Notably, these findings were refuted by a more re-
cent study from the same institution that found no difference
in the incidence of cerebral ischemic events with regard to
the use of postoperative anticoagulation.5 Consequently, be-
cause of limited and conflicting evidence, there is wide sur-
geon and institutional variability in the administration of
postoperative anticoagulation and antiplatelet therapy after
BPAV implantation.6 A recent survey of representatives
from 48 medical centers in 13 countries found that 43% of
centers routinely prescribe anticoagulation with VKA
only, 33% with ASA only, and 20% with both ASA and
VKA. Four percent of international health care centers rou-
tinely administer no antithrombotic therapy after BPAV im-
plantation.6
The biologic indication for early postoperative antithrom-
botic therapy (90 postoperative days) after BPAV implanta-
tion is to prevent thrombosis of the cloth sewing ring before
its endothelialzation.7,8 This theoretic indication for throm-
botic prophylaxis must be weighed against the risk of bleed-
ing, a potentially fatal complication that occurs with an
incidence of 1.5% to 2.4% per year9,10 and peaks during
the initiation of therapy.11 Thus, although the scientific com-
munity currently lacks appropriately powered randomized
trials assessing the need for immediate postoperative antico-
agulation in this cohort of patients, it is important that evi-
dence is brought forth evaluating the risks and benefits.
Our institutional practice has also been affected by the
lack of certainty in the literature regarding the efficacy and
necessity of early antithrombotic therapy after BPAV im-
plantation. Because much of the published evidence in-
cludes patients with risk or operative factors (eg,
concomitant operations, arrhythmias) that may confound
the risk of embolism or decision to anticoagulate,5,12-15 we
sought to be restrictive by studying only patients who under-
went isolated BPAV implantation and were discharged in
normal sinus rhythm.MATERIALS AND METHODS
From January 8, 2002, to September 29, 2008, 1131 patients underwent
BPAV implantation at Brigham and Women’s Hospital. After exclusion of1138 The Journal of Thoracic and Cardiovascular Surpatients who underwent concomitant operations (n¼ 138, 12%), who were
anticoagulated preoperatively (n ¼ 4, 0.4%), and who experienced postop-
erative refractory atrial fibrillation requiring anticoagulation at discharge
(n ¼ 128, 11%), our study base consisted of 861 patients. On the basis of
the variability of our institutional practices, patients were divided into those
who were anticoagulated with warfarin (ACþ) and those who were not
(AC). All patients who experienced a stroke in the first 24 postoperative
hours were excluded because these events were presumed to have occurred
intraoperatively and would not have been affected by postoperative antico-
agulation. Similarly, patients who experienced bleeding events in the first 24
postoperative hours were also excluded from the analysis.
All operations were performed by senior attending surgeons at Brigham
and Women’s Hospital. As a routine, surgeons do not anticoagulate with
warfarin or provide antiplatelet therapy; however, given patient-specific
risk factors, they may be inclined to do so. Specifically, the indications
for anticoagulation in this subset of patients may be widespread but are pri-
marily related to risk factors thought to make the patient at risk of TE (eg,
history of cerebrovascular accident [CVA], low ejection fraction) and are
made on a case-by-case basis. In these situations, administration of warfarin
is established when the patient is hemodynamically and clinically stable, of-
ten on the first postoperative day with a goal international normalized ratio
of 2.0 to 3.0. Comparatively, surgeons at Brigham and Women’s Hospital
are more amenable to providing antiplatelet therapy after BPAV replace-
ment. Antiplatelet therapy consists of aspirin 325 mg daily (ASAþ) and is
initiated when patients are deemed clinically stable and at low risk of major
postoperative bleeding events; in most situations, this occurs on postopera-
tive day 1. Patients were followed and censored at 90 days postoperatively
for the composite end point of TE, including the occurrence of CVA, tran-
sient ischemic attacks (TIAs), and peripheral TE. An intention-to-treat anal-
ysis was performed. Secondary end points consisted of bleeding
complications occurring within 90 postoperative days and long-term sur-
vival after BPAV implantation. The Brigham and Women’s Institutional
Review Board approved this study.Statistical Analysis
Demographic and other patient-related data were obtained from Brigham
and Women’s Hospital medical records. Follow-up information was ob-
tained from subsequent clinic visits, written correspondence from local phy-
sicians, mailed questionnaires, or direct phone contact with patients or
families. Continuous variables are expressed as a mean  standard devia-
tion. Student t tests and Pearson’s chi-square tests were used to analyze con-
tinuous and categoric variables, respectively. The primary end point
consisted of a composite outcome of TE, including CVA, TIA, and periph-
eral TE through the first 90 postoperative days. A post hoc power calculation
was performed to assess the effectiveness of this study to detect a reduction
of TE using the following parameters: a postoperative TE risk of 6% (AC)
and 2% (ACþ) based on a 1-sided alpha of 0.05. As demonstrated in Fig-
ure 1, this study exhibited moderate power (b ¼ 0.67) to assess an absolute
reduction of 4% in the incidence of TE.
On the basis of the practice patterns of our group, it was hypothesized
that the characteristics and profile of patients would differ between ACþ
and AC. Thus, to minimize treatment bias, a multivariate propensity score
model was used to create 2 risk-equal groups. All primary and secondary
end points were evaluated by adjusting for the propensity to receive antico-
agulation. A time-censored Kaplan–Meier cumulative incidence analysis
was performed to assess the incidence and distribution of TE between
ACþ and AC. All clinically relevant candidate covariates were evaluated
using logistic regression to determine significant univariate predictors of
TE. Interaction-term logistic regression models were subsequently created
to evaluate the efficacy of anticoagulation in high-risk patients identified
in the previous step.
Secondary end points consisted of bleeding events occurring within the
first 90 postoperative days (requiring rehospitalization or medical interven-
tion) and long-term survival after BPAV implantation. To analyze survivalgery c May 2010
FIGURE 1. Study power versus total sample size based on study parameters.
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compare the hazard ratios between the various methods of anticoagulation.
By using a baseline survival function estimate derived from the Kalbfleisch–
Prentice estimator16 (pages 114–118), the effect of antithrombotic therapy
on survival was assessed after propensity adjusting in all groups found to
be high risk. SAS version 9.1 and JMP version 8.0 (both from SAS Institute
Inc, Cary, NC) were used for statistical analysis.RESULTS
Table 1 demonstrates preoperative, hemodynamic, and
operative data between patients who were anticoagulated
(ACþ) and those who were not (AC). Patients electively an-
ticoagulated were older, had a higher incidence of hyperten-
sion, had a previous CVA, and were more symptomatic
preoperatively. Furthermore, mean left ventricular ejection
fractions were lower and there were increased preoperative
mean aortic gradients in instances of aortic stenosis. Of
note, there was no difference in the administration of postop-
erative ASA among those who were given postoperative an-
ticoagulation (AC; 53% [n¼ 387] vs ACþ; 53% [n¼ 71];
P ¼ .96). Although all other clinical characteristics were
similar between groups, these significant variations that
likely affected the decision to anticoagulate could not be ex-
cluded as confounders in the occurrence of TE. As such,
a 1:2 propensity model was created from the original cohort
to validate all study end points. As shown in Table 2, there
was no significant variation in clinical characteristics be-
tween ACþand AC in the propensity-matched data set.
All patients had complete 90-day postoperative follow-
up. After exclusion of neurologic events occurring within
the first 24 hours postoperatively (n ¼ 9), the incidence of
CVA, TIA, and peripheral TE was 5% (n ¼ 6) in ACþ
and 5% (n ¼ 39) in AC (P ¼ .67) groups. The overall in-
cidence of embolic events was validated with the propensity-
matched group (ACþ; n ¼ 6, 5% vs AC; n ¼ 15, 7%,
P ¼ .62). There was no difference in the incidence of TE
based on the use of postoperative ASA (ASAþ; n ¼ 26,
6%, vs ASA; n ¼ 19, 5%, P ¼ .57); this finding was con-
sistent after propensity adjusting (ASAþ; n ¼ 17, 6% vs
ASA; n ¼ 4, 8%, P ¼ .61). A time-censored cumulative
incidence analysis was performed (Figure 2) and indicatedThe Journal of Thoracic and Carthat the majority of events in both groups occurred between
postoperative days 2 and 20. After adjusting for the propen-
sity to provide anticoagulation, there continued to be no sig-
nificant difference in the distribution or freedom from TE
between ACþand AC (hazard ratio, 1.41; P ¼ .45) or be-
tween ASAþand ASA (hazard ratio, 1.44; P ¼ .38).
Univariate predictors of TE are shown in Table 3; age, fe-
male gender, short stature, smoking status, severe symptom-
atology (New York Heart Association [NYHA] III/IV), and
a 19-mm prosthesis were found to increase the likelihood of
TE. Because of the small number of TE events, amultivariate
model with high statistical validity was unable to be created;
however, covariate correlations were found to be highly sig-
nificant. Of the 95 patients who had 19-mm aortic valves im-
planted, 89 (94%) were female (c2 ¼ 112, P< .0001).
Furthermore, female patients were older (72.44 11.4 years
vs 68.0 13.5 years, P<.0001), more likely to be in NYHA
III/IV (n ¼ 164, 44% vs n ¼ 143, 29%, c2 ¼ P< .0001),
more likely to be shorter compared with their male counter-
parts (160.19  7.4 cm vs 175.72  8.89 cm, P< .0001),
and less likely to be smokers (n ¼ 234, 52% vs n ¼ 136,
33%, P< .0001).
To investigate whether antithrombotic therapy affected
the occurrence of TE in these high-risk groups, logistic re-
gression interaction terms were created with each univariate
predictor and each method of antithrombotic therapy (ASA
and warfarin). As shown in Table 4, the use of either ASA or
VKA postoperatively decreased the risk of TE in female pa-
tients and those with a 19-mm BPAV. Furthermore, patients
in NYHA III/IV who were anticoagulated with VKA had
a lower incidence of TE in the postoperative period com-
pared with those in NYHA III/IV who were not; this trend
was also appreciated in patients who were given ASA post-
operatively (P ¼ .06).
There was no significant increase in the incidence of
bleeding at 90 days in patients who were anticoagulated
postoperatively (ACþ; n ¼ 6, 4.6% vs AC; n ¼ 20,
2.8%, P ¼ .29). This finding was consistent in the propen-
sity-matched cohort (ACþ n ¼ 6, 5%, AC n ¼ 8, 3.5%,
P ¼ .44).diovascular Surgery c Volume 139, Number 5 1139
TABLE 2. Propensity-matched cohort demographic and operative
patient characteristics
Propensity-matched cohort
Postoperative
anticoagulation
(n ¼ 116)
No postoperative
anticoagulation
(n ¼ 232)
P
value
Age (y) 75.14  8.83 74.97  9.07 .87
Weight (kg) 79.92  17.65 78.89  16.18 .76
Height (cm) 168.45  10.76 166.92  12.36 .26
Smoking history, n (%) 56 (48%) 116 (50%) .76
Hypertension, n (%) 95 (82%) 194 (84%) .69
Diabetes, n (%) 22 (19%) 53 (23%) .41
Hyperlipidemia, n (%) 82 (71%) 156 (67%) .51
Baseline creatinine 1.21  0.81 1.12  0.61 .3
Renal failure, n (%) 9 (8%) 13 (6%) .44
History of CVA, n (%) 7 (6%) 8 (4%) .26
Peripheral vascular
disease, n (%)
20 (17%) 40 (17%) .99
Cerebrovascular disease,
n (%)
17 (15%) 31 (13%) .74
NYHA functional status
I 91 (16%) 44 (19%) .91
II 43 (37%) 87 (38%)
III 50 (43%) 92 (40%)
IV 4 (3%) 9 (4%)
Previous surgical
interventions
Previous CABG, n (%) 14 (12%) 31 (13%)
Previous valve
procedures, n (%)
0 0
Echocardiographic data
Ejection fraction 55.44  12.47 57.92  10.83 .07
Mean PAP 27.92  11.92 26.67  10.26 .66
Aortic stenosis 101 (87%) 206 (89%) .64
Aortic gradient 50.94  19.64 49.26  18.44 .48
Moderate or greater
aortic regurgitation
61 (53%) 108 (47%) .29
Operative characteristics
CPB time (min) 123.37  57.65 114.2  57.84 .16
Crossclamp time 79.35  33.58 76.95  39.16 .57
Prosthesis size 23 (21–25) 23 (21–25) .07
CVA, Cerebrovascular accident; NYHA, New York Heart Association; CABG, coro-
nary artery bypass grafting; PAP, pulmonary artery pressure; CPB, cardiopulmonary
bypass.
TABLE 1. Demographic, hemodynamic, and operative patient
characteristics of total cohort
Complete cohort
Postoperative
anticoagulation
(n ¼ 133)
No postoperative
anticoagulation
(n ¼ 728)
P
value
Age 74.54  9.1 68.95  13.1 <.0001
Weight (kg) 79  19 80  18 .48
Height (cm) 168  10.8 169.21  10.8 .44
Smoking history, n (%) 65 (49%) 348 (48%) .82
Hypertension, n (%) 109 (81%) 452 (62%) <.0001
Diabetes, n (%) 24 (18%) 121 (17%) .68
Hyperlipidemia, n (%) 92 (69%) 440 (60%) .06
Baseline creatinine 1.29  1.36 1.08  0.6 .07
Renal failure, n (%) 11 (8%) 30 (4%) .04
History of CVA, n (%) 14 (6%) 24 (3%) .02
Peripheral vascular
disease, n (%)
19 (14%) 76 (10%) .19
Cerebrovascular disease,
n (%)
29 (13%) 83 (11%) .29
NYHA functional status .0002
I 20 (15%) 161 (22%)
II 44 (33%) 330 (45%)
III 60 (45%) 214 (29%)
IV 9 (7%) 23 (3%)
Previous surgical
interventions
Previous CABG, n (%) 18 (14%) 76 (10%) .29
Previous valve
procedures, n (%)
0 0
Echocardiographic data
Ejection fraction 54  13 58  11 .007
Mean PAP 28  12 25  12 .26
Aortic gradient 44  20 48  18 .04
Moderate or greater aortic
regurgitation
65 (49%) 343 (47%) .7
Operative characteristics
CPB time (min) 125  59 111  53 .02
Crossclamp time 80  36 75  36 .77
Prosthesis size 23 (21–25) 23 (21–25) .07
CVA, Cerebrovascular accident; NYHA, New York Heart Association; CABG, coro-
nary artery bypass grafting; PAP, pulmonary artery pressure; CPB, cardiopulmonary
bypass.
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Long-term follow-up was available for 855 patients
(99%) at a mean of 3.82  2.22 years. After propensity ad-
justing, the use of ASA (Figure 3, A) or VKA (Figure 3, B)
did not seem to influence survival. All high-risk groups (Ta-
ble 3) were evaluated on the basis of method of anticoagula-
tion (ASA Figure 3, C, E, G; VKA Figure 3, D, F, H); there
were no significant differences in survival based on the
method of anticoagulation in these subsets.
DISCUSSION
The present study was designed to detect whether postop-
erative antithrombotic therapy with warfarin or ASA in the
first 90 postoperative days is protective against the occur-1140 The Journal of Thoracic and Cardiovascular Surrence of TE. The overall incidence of TE in patients who un-
derwent isolated BPAV discharged in normal sinus rhythm
was low and did not differ on the basis of the type or lack
of antithrombotic therapy. These results are in stark contrast
with a previous study4 that observed an extremely high rate
of TE in patients who were not anticoagulated with intrave-
nous low-molecular-weight heparin and VKA. Although
this discrepancy is not easily explained, it is reassuring
that subsequent studies have found that providing antithrom-
botic therapy for the first 90 postoperative days provides no
appreciable reduction in the incidence of TE.5,13,15 Despite
this evidence, however, many medical and surgical societiesgery c May 2010
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FIGURE 2. Cumulative incidence analysis (composite of stroke, TIA, and peripheral thromboemboli). TE, Thromboembolism.
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D(eg, American Heart Association/American College of Car-
diology,2 American College of Clinical Pharmacy,17 Euro-
pean Society of Cardiology17) have taken the conservative
approach6 and continue to recommend antithrombotic ther-
apy. This study examined a highly select group of patients
(isolated BPAV in normal sinus rhythm at discharge) and
rigorously adjusted for potential confounders of TE to
hone into the causal association between BPAV and TE.
As such, this study emphasizes that the use of VKA or
ASA is not indicated for widespread use in patients undergo-
ing BPAV implantation.
As is the casewith the current analysis, most studies exam-
ining the necessity of VKA or ASA prophylaxis after BPAV
implantation have been retrospective and are limited by se-
lection bias.4,5,11,15,18,19 Comparatively, the few prospective
studies performed have been grossly underpowered,13,20 and
thus do not provide adequate evidence to justify any practice-
changing conclusions. Despite this lack of level I evidence,
many studies have observed similar trends with regard to
the use of early anticoagulation. In one of the largest series
to date, Sundt and colleagues5 did not find a decrease in
the risk of cerebral ischemic events in patients anticoagulated
after BPAV implantation. In a similarly designed study,Moi-
nuddeen and colleagues15 also failed to appreciate a reduc-
tion in cerebral ischemic events in patients who were
administered low-molecular-weight heparinþVKA versus
those given no anticoagulation. Others have studied the
risk of TE in patients administered antiplatelet agents versus
low-molecular-weight heparinþVKA and have also found
no reduction in the incidence of TE.11,19 Notably, despite
failing to reduce the incidence of TE events, early anticoagu-TABLE 3. Univariate predictors of thromboembolism
Univariate predictors of thromboembolism
Covariate Odds ratio
Age 1.03 (1.003–1.05)
Female gender 2.23 (1.27–3.93)
Height (cm) 0.96 (0.94–0.98)
Smoking history 1.77 (1–3.16)
NYHA III/IV 1.77 (1.01–3.07)
19-mm BPAV prosthesis 2.22 (1.10–4.46)
NYHA, New York Heart Association; BPAV, bioprosthetic aortic valve.
The Journal of Thoracic and Carlation in this group of patients has never been shown to in-
crease the risk of bleeding events, a finding that is
reaffirmed with the present study. Although it seems that
this study merely confirms the findings of previous reports,
there are important differences between our study design
and those that have predated it. First, we excluded all patients
undergoing concomitant procedures and those requiring an-
tithrombotic therapy. We also included all ischemic events,
including CVAs, TIAs, and peripheral embolic events,
thereby explaining why the incidence of TE in our study
(5%) is higher than previously reported (2%5,15,18). Fi-
nally, to minimize treatment bias, we used multivariate pro-
pensity analysis. We believe these modifications to the study
design allowed us to more accurately investigate the associ-
ation between BPAV and TE and the potential mitigation
that might occur as the result of antithrombotic therapy. Al-
though the conclusion that widespread early anticoagulation
offers minimal benefit is consistent with previous studies,
our restrictive inclusion criteria and study design allowed
us to identify trends thatmore clearly define the role of antith-
rombotic therapy after BPAV implantation.
Consistent with other analyses, our univariate analysis
identified that increasing age18 and smoking history11 are in-
dependent predictors of TE. We also identified a number of
variables that have not been implicated, such as female gen-
der, short stature, severe symptomatology (NYHA III/IV),
and implantation of a 19-mm aortic BPAV. The association
between TE and depressed left ventricular function has been
described18 and may explain the observed finding that pa-
tients in NYHA III/IV experienced postoperative TE at
a higher rate than those who were minimally symptomatic.
The other covariates implicated in this study (female gender,
small stature, and 19-mm prosthesis) have not been de-
scribed and bring into the question the physiologic and bio-
chemical phenomena at work. In an effort to build
a multivariate model, it became evident that we would be un-
able to do so with statistical robustness because of the high
level of intercovariate correlation. For example, nearly all
19-mm prostheses were used in female patients. Also, fe-
male patients were shorter, older, less frequently smokers,
and more likely to be in preoperative NYHA III/IV. Conse-
quently, we do not believe all univariate predictors arediovascular Surgery c Volume 139, Number 5 1141
TABLE 4. Mitigation of postoperative thromboembolus in high-risk patient groups
ACþ (vs AC) P value ASAþ (vs ASA) P value
Age 0.99 (0.99–1.00) .14 1.005 (0.998–1.013) .18
Female gender 0.75 (0.58–0.97) .03 0.66 (0.46–0.93) .02
Height (cm) 1.002 (0.99–1.006) .22 0.99 (0.996–1.002) .62
Smoking history 0.79 (0.61–1.03) .08 1.27 (0.92–1.77) .15
NYHA III/IV 0.73 (0.55–0.98) .04 0.34 (0.10–1.07) .06
19-mm BAV prosthesis 0.65 (0.45–0.93) .02 0.36 (0.16–0.81) .01
ASA, Acetylsalicylic acid; NYHA, New York Heart Association; BAV, bioprosthetic aortic valve.
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concerning, however, and warrant further investigation,
and should be taken into account when making a decision
about providing early postoperative antithrombotic therapy.
Thrombi consist of thin fibrin strands and platelet aggre-
gate21 that occur primarily on the BPAV cloth sewing ring
before endothelialzation.7,8 Primary factors facilitating the
formation of thrombi in the context of BPAV implantation
include high laminar blood flow22 and a thrombogenic sur-
face. Although not universally true, patients with 19-mm
valves are those most likely to experience high orifice blood
flow as the result of narrow valve dimensions; thus, theoret-
ically, they are highly susceptible to thrombi formation.
Notably, there is a wide body of literature describing pros-
thesis–patient mismatch (PPM); the general consensus being
that severe PPM in patients undergoing BAV implantation
negatively affects long-term survival.23-25 Although PPM
was not specifically addressed in this study, Tasca and col-
leagues26 previously found that more than 90% of patients
with a 19-mm BAV have the most severe form of PPM. In-
vestigators have not studied the role of PPM in postoperative
TE; however, it is curious that female patients, those with
19-mm valves, and patients with short stature had a signifi-
cantly higher risk of postoperative TE. We can only specu-
late that PPM is causally related to this finding but do believe
valve size and particularly PPM (a variable linking 2 of our
univariate predictors) are important to consider when decid-
ing to provide early postoperative anticoagulation after
BPAV implantation.
Because of the variety of practices at Brigham and
Women’s Hospital, we were able to retrospectively examine
whether antithrombotic therapy affected the occurrence of
TE in the high-risk groups we identified (Table 3). By creat-
ing interaction logistic regression models with each method
of antithrombotic therapy, we found that certain groups of
patients may have benefited by some form of antithrombotic
therapy. Female patients who were given warfarin and those
who were given ASA postoperatively had a lower risk of TE
compared with female patients who were not given antith-
rombotic therapy. Furthermore, patients with a 19-mm
BPAV were also protected from TE when provided warfarin
or ASA postoperatively. The final subset of patients who
were offered TE protection were those in NYHA III/IV;
these patients achieved a 35% to 65% relative reduction1142 The Journal of Thoracic and Cardiovascular Surin the incidence of TE when given either warfarin or ASA.
In summary, these findings suggest that TE may be signifi-
cantly affected by BPAV prosthesis size and preoperative
cardiovascular function. Thus, strong consideration of im-
mediate antithrombotic therapy should be given to these
subsets of patients.
LIMITATIONS
All retrospective studies have inherent limitations, such as
treatment bias and confounding, that can merely be ad-
dressed but not completely eradicated. We believe we
have eliminated confounders by restricting our cohort to
those undergoing isolated BPAV who were discharged in
normal sinus rhythm.18 After examining the differences in
characteristics between ACþ and AC, it was evident that
treatment bias was certainly a limitation and would affect in-
terpretability of this study. As such, we used a multivariate
propensity analysis to account for this bias. Despite these
manipulations, we were still able to attain moderate power
in our ability to detect a significant difference in the inci-
dence of early postoperative TE. Unfortunately, this study
was not designed or powered to assess the optimal method
of antithrombotic therapy. Our analyses did, however, allow
us to identify high-risk groups who may benefit from antith-
rombotic therapy and provide important data for future pro-
spective randomized investigations. Although these results
should be analyzed with scrutiny, we maintain that because
of our study design and end points of interest, this report
brings to light information that has not previously been de-
scribed and is critically important to the postoperative treat-
ment of patients undergoing BPAV implantation.
CONCLUSION
Early antithrombotic therapyafterBPAVremains a contro-
versial topic highlighted by a high degree of institutional and
surgeon variability. The majority of medical societies con-
tinue to recommend antithrombotic therapy for 90 postoper-
ative days; however, this recommendation seems to be based
on reports with conflicting results and significant limitations.
On the basis of our findings, postoperative antithrombotic
therapy should be considered for patients at high risk of
TE, including female patients, those with a small aortic pros-
thesis, and those who are severely symptomatic preopera-
tively. The risk of TE that is reduced in high-risk patients isgery c May 2010
FIGURE 3. Long-term survival using the Cox proportional hazard approximation. ASA, Acetylsalicylic acid; NYHA, New York Heart Association.
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Dlikely secondary to prevention of thrombus formation in
high-flow circumstances (19-mm BPAV) and depressed
cardiac function (NYHA III/IV). Unfortunately, the mode
of antithrombotic therapy that offers optimal prevention
whileminimizing bleeding risks remains unclear. Future pro-
spective randomized studies will be necessary to investigate
the role of antithrombotic therapy to develop evidence-based
recommendations of the highest statistical certainty.The Journal of Thoracic and CarReferences
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Dr Steven W. Guyton, MD (Portland, Ore). We don’t know if
anticoagulation is beneficial in this group of patients, but we, as you
noted, have seen that it doesn’t cause dramatic increases in bleeding
perioperatively. You noted the lack of appropriately powered ran-
domized trials of postoperative anticoagulation. This again is a ret-
rospective study and limited by selection bias, treatment bias, and
confounding. There seems to be some confusion in the article in
that you note that this confounding cannot be completely eradi-
cated, but in the next sentence you say ‘‘we have eliminated con-
founders by further restrictions on the data.’’ You tried to
decrease the bias of this retrospective study by a propensity-based
analysis, but one of your strongest conclusions is that 19-mm
valves are at higher risk, yet in your propensity analysis all the
19-mm valves dropped out. Can you try to explain that?
Dr Elbardissi. I’m not sure I understand your question, can you
please rephrase it?
Dr Guyton. When I looked at your propensity analysis data
sheet, the range of valve size was from 21 to 25 mm. All the 19-
mm valves were gone.
Dr Elbardissi. You are looking at the interquartile range. The
25th percentile was the 21-mm valve, and the 75th percentile was
the 25-mm valve.
Dr Guyton. I see, so it was not a range. It’s an interquartile. All
right. That was not clear from the data. Now your institutional prac-
tice during this study seems to have been determined by individual
surgeons. Is that correct?
Dr Elbardissi. That is correct.
Dr Guyton. And yet you note that the majority do not anticoa-
gulate with low-molecular-weight heparin, VKAs, or provide anti-
platelet therapy, but 54% of your anticoagulation-negative patients
were discharged on aspirin. It seems to me that more than half of
them had anticoagulation or aspirin.
Dr Elbardissi. That’s true. With regard to VKAs (warfarin spe-
cifically in this case), the majority of surgeons at our institution will
not anticoagulate. As you saw from my first table, there are certain
preoperative characteristics that would incline one to do so, primar-
ily in patients who are thought to be at a relatively high risk of TE.
The inclination not to provide some form of antiplatelet therapy is
less pronounced. You are correct that approximately one half of the
cohort was given aspirin, which is consistent with a more liberal
practice pattern that we observed at our institution.
Dr Guyton. Some of the conclusive statements in the article are
hidden in the body of the article where you say that VKAs or aspirin
is not indicated for widespread use in BPAV implantation and
widespread early anticoagulation offers minimal benefit. More
than half of both of your categories of anticoagulation negative/an-
ticoagulation positive were on aspirin and your final conclusion
says postoperative antithrombotic therapy should be considered
for female patients, patients with small aortic prostheses, and pa-
tients who are severely symptomatic preoperatively. It is a little un-
clear whether you are recommending anticoagulation or
antithrombotic therapy.
Dr Elbardissi. The objective of our study was not to assess the
best type of antithrombotic therapy (aspirin vs warfarin). That be-
ing said, it would have been easy to end our analysis by looking
at the thromboembolic risk with regard to anticoagulation or anti-
platelet therapy. We took it one step further, identified risk factorsgery c May 2010
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efficacious. Because our study was not designed to assess whether
antiplatelet therapy or anticoagulation is more beneficial than the
other, we leave it open to the readers to make that assertion on
the basis of their interpretation of our data.
Dr Guyton. I agree with that. I think the important thing is that
you potentially identified areas that require additional randomized
trials to try and evaluate them.
Dr Thoralf Sundt, MD (Rochester, Minn). Drew, that was
beautifully presented. For those in the audience who do not
know, Drew was a Mayo medical student, and so we will proudly
take credit for all of his subsequent success throughout his career. I
appreciate you quoting me in your presentation because I intend to
quote you later on this morning.
Can you give us an idea about what you think the mechanism is
for this effect, the reduction in thromboembolic events, specifically
in this subset of patients. I have my own thoughts, but I would be
interested in yours first.
Dr Elbardissi.With regard to forming clot, the theory is that clot
forms on the prosthetic sewing ring. As such, youwant to anticoagu-
late or provide some form of antithrombotic therapy until endotheli-
alization of the sewing ring occurs. That being said, why are we
finding that certain subsets of patients have a higher risk of TE com-
paredwith the remainder of our cohort? I think this has to dowith the
small size of the valve and depressed left ventricular function. First,
it is important to note that we only identified univariate predictors of
TE,meaning that each predictor is not necessarily causally related to
TE andmay in fact demonstrate variability in the dataset thatwe can-
not further characterize. According to my own rigorous analysis of
the data and knowing how each of these predictors function, it is
my theory that it comes down to the 19-mm valve and depressed
left ventricular function. Why? We know from my previous labora-
tory studies that high laminar flow and decreased ejection fraction
can both contribute to the incidence of thrombus formation.
Dr Sundt. I will give you an alternative hypothesis for what it’s
worth. I’ll bet you a Coke in a bottle that what this really is a matter
of silent postoperative atrial fibrillation. I think the markers you
have looked at are markers of postoperative atrial fibrillation, and
I’ll bet it has nothing to do at all with endothelialization of the sew-
ing ring of the valve. It is just postoperative atrial fibrillation, and
the people who are at high risk for that, most of which is unrecog-
nized, are those with silent atrial fibrillation, and those who are anti-
coagulated are protected. Of course I have no proof of that, but you
might look at your left atrial size in your cohort or something likeThe Journal of Thoracic and Carthat as another predictor of atrial fibrillation. That is another thing to
consider.
Dr Craig Baker, MD (Los Angeles, Calif). At our institution,
we do not routinely anticoagulate bioprosthetic valves; we have
seen 2 cases in the last couple years of very early bioprosthetic
valve deterioration. It is difficult to describe, but it presents as ag-
gressive calcium and platelet deposits. Dr Damiano’s group de-
scribed a similar phenomena a couple of years ago in 4 patients. I
contacted him, and it is their practice not to anticoagulate patients
either. I am curious in your extensive review of all your patients,
did you have this phenomenon in your approximately 1000 pa-
tients? If you did, did you see it in anticoagulated or unanticoagu-
lated patients?
Dr Elbardissi. That is not something that we initially looked for
when reviewing these patients. It was not a hypothesis that I knew
existed with regard to the causes of TE in this cohort of patients, but
it is something interesting that we can certainly look at.
DrNimesh Desai, MD (Philadelphia, Pa). One quick comment
about the 19-mm valve hypothesis. In our experience, and this is
borne out in the literature, patients who receive 19-mm valves are
just a different group of patients. They are older. They are female.
They are sick. They have severe atherosclerosis. Their valves are
tremendously calcified. Their roots are calcified. Their ascending
aortas have calcium in them, as do their arches. Although there is
certainly a scientific hypothesis that a smaller valve that has dif-
ferent flow characteristics may be more thrombogenic, these pa-
tients are at risk for stroke for any cardiac operation and are
actually at elevated risk for stroke even if they didn’t have heart
surgery.
Dr Elbardissi. I appreciate that comment. If we only looked at
the predictors of TE, I agree that it would be hard to endorse pro-
viding some form of antithrombotic therapy. However, we had
enough variability in our practice patterns to evaluate whether ei-
ther form of antithrombotic therapy was efficacious in this group.
In fact, we saw a reduction in the incidence of TE in patients
with 19-mm valves. This indicates that regardless of the cause,
we should at least be aware of the potential risk reduction that exists
with antithrombotic therapy when implanting these valves and be
aggressive by providing at least aspirin postoperatively.
Dr Desai. In your model did you correct for the presence of pe-
ripheral vascular disease or cerebrovascular disease?
Dr Elbardissi. Yes. Initially, anticoagulated patients had
a higher incidence of peripheral vascular disease. After propensity
adjustment, that was no longer significant.diovascular Surgery c Volume 139, Number 5 1145
